WO2005102306A1

WO2005102306A1 - Anti-inflammatory analgesic adhesive patch

Info

Publication number: WO2005102306A1
Application number: PCT/JP2005/007590
Authority: WO
Inventors: Koji Tanaka; Yasunori Takada; Miyuki Shinmura; Eiji Hashimoto
Original assignee: Hisamitsu Pharmaceutical Co., Inc.
Priority date: 2004-04-23
Filing date: 2005-04-21
Publication date: 2005-11-03
Also published as: TWI379667B; JPWO2005102306A1; JP4764337B2; TW200538087A

Abstract

[PROBLEMS] To provide an anti-inflammatory analgesic adhesive patch which is excellent in percutaneous absorbability and stability and is reduced in irritation to the skin. [MEANS FOR SOLVING PROBLEMS] The anti-inflammatory analgesic adhesive patch comprises a rubber-based pressure-sensitive adhesive and is characterized by having a drug layer which contains diclofenac sodium, an organic acid which is solid at room temperature, and crotamiton. It may be characterized by being obtained by mixing an organic acid which is solid at room temperature and diclofenac sodium with crotamiton to dissolve the former ingredients and kneading the solution together with a rubber-based pressure-sensitive adhesive.

Description

Anti-inflammatory analgesic patch

Technical field

The present invention relates to a transdermal patch containing an anti-inflammatory analgesic, excellent in stability and transdermal absorption, and less irritating to the skin. More specifically, the present invention relates to a rubber-based pressure-sensitive anti-inflammatory analgesic patch comprising sodium diclofenac, an organic acid which is solid at room temperature, and crotamiton.

Background art

[0002] Sodium diclofenac (2 — [(2,6-dichlorophenyl) amino] benzeneacetic acid monosodium salt) was obtained in 1965 by Salimann et al. Of Ciba-Geigy, Switzerland. It is a non-steroidal anti-inflammatory drug that has been newly developed.It is effective for internal use in diseases such as rheumatoid arthritis and osteoarthritis, analgesia and antipyretic effects, and 0.1% eye drops prevent postoperative inflammation. It is applied to stop and so on. On the other hand, recently developed topical 1% gel is used for osteoarthritis and muscle pain. Dosage is 75-LOOmg daily as diclofenac sodium for internal use.

[0003] Diclofenac sodium is an excellent non-steroidal anti-inflammatory drug, an analgesic. When administered orally, diclofenac sodium is used as an active ingredient because it has side effects such as gastrointestinal disorders. Various topical external preparations have been developed. Recently, in Japan, diclofenac sodium-containing tape preparations have been approved as pharmaceuticals, and overseas, diclofenac sodium cataplasms, diclofenac getylamine salt cataplasms and patches have been proposed.

However, although diclofenac sodium is hardly soluble in ether, it is relatively soluble in water and has insufficient transdermal absorbability, and various measures have been taken.

For example, an anti-inflammatory analgesic patch with improved solubility and percutaneous absorption of diclofenac sodium, which is formed by laminating a pressure-sensitive adhesive layer containing diclofenac sodium and an organic acid on a flexible support (Patent Document 1), which contain non-steroidal anti-inflammatory drug salt compounds, organic acids, and glycos, and have high solubility in the base component and high keratin permeability. Agent (see Patent Document 2), diclofenac sodium, crotamiton, and dissolution aids for fatty acids that are liquid at room temperature and have 6 to 18 carbon atoms, such as 2-ethylheptanoic acid, pelargonic acid, caprylic acid, oleic acid, and linoleic acid. Diclofenac sodium-containing patch (see Patent Document 3), (i) diclofenac sodium, (ii) polycarboxylic acid polyalkyl ester, medium-chain fatty acid triglyceride or crotamiton. At least one kind of oil, (iii) fatty acid which is liquid at normal temperature, (iv) hydrophilic surfactant, and (V) diclofenac sodium-containing OZW type emulsion containing water are contained in the plaster of the patch. Diclofenac sodium-containing patch characterized by being dispersed (see Patent Document 4), drug, crotamiton, rubber-based adhesive, fluid It has excellent drug release and sustainability, containing paraffin, a patch with good support feeling, which has a strong support (see Patent Document 5), an anti-inflammatory analgesic, crotamiton, and a styrene-isoprene-styrene block copolymer. Anti-inflammatory analgesic patch

(See Patent Document 6), diclofenac sodium, an organic acid, a pyrrolidone (derivative), and an adhesive plaster containing a polyhydric alcohol fatty acid ester, which has high transdermal absorption of diclofenac sodium! An oily analgesic anti-inflammatory local action patch (see Patent Document 7) and the like have been reported. It also has a drug storage layer containing clofenac sodium and an organic acid at a weight ratio of 1: 0.1 to 1: 5.0, a diffusion control membrane for diclofunac sodium, and a lipophilic adhesive layer that can be attached to the skin. Patches for systemic administration characterized by the following facts have also been reported. Examples of such organic acids include oleic acid, linoleic acid, linolenic acid, isostearic acid, myristic acid, lactic acid, citric acid, oxalic acid, and acetic acid. Are reported to be used (see Patent Document 8).

[0004] As described above, a number of external preparations have been proposed. However, they have excellent transdermal absorbability, low irritation to the skin, and excellent storage stability over time, and are effective, safe, and stable. Practical external preparations with excellent properties have been sufficiently developed!

Patent Document 1: JP-A-61-280426

Patent Document 2: JP-A-62-181226

Patent Document 3: JP-A-7-89853

Patent Document 4: JP-A-6-219940

Patent Document 5: JP-A-9 291028 Patent Document 6: JP-A-4-321624

Patent Document 7: JP-A-2002-338462

Patent Document 8: JP-A-11 322595

Disclosure of the invention

Problems to be solved by the invention

[0006] The present invention provides an anti-inflammatory analgesic patch which is excellent in percutaneous absorbability and stability, and has low irritation to the skin. It is another object of the present invention to provide an external preparation of diclofenac sodium which has excellent storage stability without precipitating crystals of the active ingredient even when stored for a long time.

Means for solving the problem

[0007] The present inventors have been conducting various studies to develop an external preparation having excellent efficacy and safety, and it is preferable to use a solid organic acid in order to increase the absorption of diclofenac sodium. I have found that. However, when a solid organic acid was used, it was found that an organic acid having poor stability over time of the drug product was precipitated, and improvement to prevent such precipitation was required. Therefore, the inventors of the present invention have studied methods for preventing strong precipitation of various solvents, and have found that crotamiton has an excellent precipitation-preventing action. In addition, surprisingly, such formulations have significantly reduced skin irritation compared to the prior art of (crotamiton + polyhydric alcohol) absorption enhancing compositions, and diclofenac sodium and organic acids are re-established in the formulation. A base composition and a production method that do not crystallize and have high transdermal absorption of diclofenac sodium have been found.

[0008] That is, the present invention relates to an anti-inflammatory analgesic patch comprising a rubber-based pressure-sensitive adhesive, characterized in that the drug layer contains diclofenac sodium, an organic acid which is solid at room temperature, and crotamiton. And more specifically, by mixing and dissolving a solid organic acid and diclofenac sodium at room temperature in crotamiton and kneading the solution with a rubber-based adhesive. The present invention relates to an anti-inflammatory analgesic patch which also contains diclofenac sodium, an organic acid which is solid at room temperature, and crotamiton, and which has a rubbery adhesive strength.

Further, the present invention provides a crotamiton with an organic acid and diclofenac sodium which are solid at room temperature. Mixing and dissolving, and kneading the solution with a rubber-based pressure-sensitive adhesive, wherein the drug layer contains sodium diclofenac, a solid organic acid at room temperature, and crotamiton; The present invention relates to a method for producing a patch.

[0009] The anti-inflammatory analgesic patch of the present invention comprises a support, an adhesive layer containing a drug layer, and a release film. When used, the release film is peeled off, and the adhesive layer containing the drug layer is peeled off. Use by attaching to the skin.

The adhesive layer of the patch of the present invention contains at least diclofenac sodium, crotamiton, an organic acid which is solid at room temperature, and a rubber-based adhesive. The pressure-sensitive adhesive layer may form a single layer in which these components are mixed, or may be composed of a layer containing a rubber-based pressure-sensitive adhesive and a drug layer containing a drug.

[0010] The "solid state" of the organic acid that is solid at room temperature in the present invention means that it is in a solid state at room temperature, and more specifically, the organic acid that is solid at room temperature according to the present invention. It is an organic acid having a melting point of room temperature or higher, usually 30 ° C or higher. Preferred organic acids in solid form at room temperature in the present invention include citric acid, tartaric acid, lactic acid, glycolic acid, succinic acid, maleic acid, fumaric acid, and malic acid. It is an acid.

More preferred room temperature solid organic acids of the present invention include one or more selected from group consisting of citric acid, tartaric acid, lactic acid, glycolic acid, and malic acid. , And the like. More preferred room temperature solid organic acids include one or more selected room temperature organic hydroxycarboxylic acids selected from the group consisting of citric acid, tartaric acid, and malic acid. Preferably, specific examples of the organic hydroxycarboxylic acid which is solid at room temperature include citric acid, tartaric acid and the like.

The organic acid which is solid at room temperature in the present invention can be added in a large amount as long as it can improve the transdermal absorbability of diclofenac sodium. And the need for large amounts of solvent. The preferred amount is about 0.01 to 10 parts by weight, about 0.1 to 5 parts by weight, or about 0.1 to 1 part by weight, preferably about 1 to 1 part by weight, based on 1 part by weight of diclofenac sodium as an active ingredient. 0.3 to 1 part by weight. Further, the amount of the adhesive layer of the patch of the present invention is 0.0. 5 to: LO weight%, preferably 0.1 to 5 weight%, 0.1 to 2 weight%.

[0011] As components used in the present invention for preventing the precipitation of organic acid solid crystals at room temperature, diclofenac sodium at room temperature and organic acids solid at room temperature can be almost completely dissolved. A solvent is used. Examples of such a solvent include N-methyl-pyrrolidone, crotamiton, methanol, and the like. Considering the compatibility with the rubber-based pressure-sensitive adhesive in the adhesive patch of the present invention and the stability of the pressure-sensitive adhesive layer, Methylpiperidone and crotamiton are preferred.

It has been found in the present invention that the use of crotamiton is preferred in terms of skin irritation, although the precipitation of organic acid crystals can be prevented by adding such a solvent (see below). Comparative Example 2).

The amount of crotamiton used in the present invention is not particularly limited as long as the amount of the organic acid crystals can be prevented, but is preferably 1 to 20% by mass, 2 to: L0% by mass, More preferably, it is about 2 to 8% by mass.

The rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is a non-aqueous or anhydrous pressure-sensitive adhesive layer composed of a pressure-sensitive adhesive composition mainly composed of natural or synthetic rubber. The pressure-sensitive adhesive composition contains a natural and / or synthetic rubber, a tackifying resin and a softening agent, and may further contain other additives according to the purpose.

The synthetic rubber used for the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is polyisoprene, polyisobutylene, polybutadiene, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene block copolymer, styrene- The butadiene rubber, styrene-isoprene rubber and / or group strength are also selected from one or more types. Preferred rubbers include styrene-isoprene-styrene block copolymer, polyisobutylene and the like. The ratio of natural or Z or synthetic rubber in the whole rubber-based adhesive layer is preferably about 10 to 40% by mass and about 20 to 40% by mass.

The tackifying resin used for the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is not particularly limited as long as it is generally used, but polyterpene resin, rosin ester resin, hydrogenated rosin ester; Fats, alicyclic saturated hydrocarbon resins, terpene phenol resins, petroleum resins and the like are preferably used. Adhesion occupies the entire rubber-based adhesive composition The ratio of the fat and oil is preferably 10-40% by mass.

The softening agent used for the rubber-based pressure-sensitive adhesive of the pressure-sensitive adhesive layer of the patch of the present invention is not particularly limited as long as it is a commonly used one, but liquid paraffin, polybutene, liquid polyisobutylene, animal and vegetable oils and the like are preferably used. . The proportion of the softening agent in the whole rubber-based pressure-sensitive adhesive layer is preferably 20 to 70% by mass and 30 to 70% by mass.

[0013] The adhesive layer of the patch of the present invention may further contain various additives as necessary. Examples of such additives include drugs, absorption enhancers, fillers, antioxidants, ultraviolet absorbers, fragrances, dyes, and the like.

As a drug, in addition to diclofenac sodium, it can be caloric in expectation of a synergistic therapeutic effect, etc., and it can be used as a hot pepper component (such as capsaicin), a warming agent such as nonyl acid ヮ -lylamide, a cooling agent such as menthol, Essential oil components and others (plant extracts, tocopherol acetate, etc.) can be exemplified.

Examples of the absorption promoter include aliphatic alcohols such as oleyl alcohol, fatty acids such as oleic acid, metal salts of fatty acids such as sodium stearate, and fatty acid esters. Examples of the filler include silicic anhydride, aluminum silicate and the like.

[0014] The support of the patch of the present invention includes polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, butyl acetate-vinyl chloride copolymer, polyvinyl chloride, polyamide, polyester, nylon, cellulose derivative, A film, a sheet, a sheet-like porous body, a sheet-like foam, a woven fabric, a knitted fabric, a nonwoven fabric, a paper, or a laminate thereof of a synthetic resin such as polyurethane can be used. Stretchable materials such as knitted fabrics are preferred from the viewpoint of securing the adhesiveness of the patch to the skin. Further, those having self-supporting property are preferred in terms of the nodling property of the patch.

On such a support, it can be applied or spread so that the thickness of the adhesive layer is 10 to 500 μm, preferably 30 to 300 μm.

As the release film of the adhesive patch of the present invention, polyester, polypropylene, polyethylene, paper, or a laminate obtained by applying a release treatment (such as silicone coating) to a sheet-like material having a laminate strength is preferably used. [0015] The method for producing the patch of the present invention is a force that can be produced according to the usual method for producing a non-aqueous or anhydrous patch. Preferred production methods include crotamiton and solid at room temperature. Each of the organic acid and diclofenac sodium is mixed and dissolved, and the resulting solution is kneaded with a rubber-based pressure-sensitive adhesive prepared by kneading to prepare a composition to be a pressure-sensitive adhesive layer. It can be manufactured by spreading it on a body by coating or the like, and then bonding a release film. Further, if necessary, the product can be cut into an appropriate size to obtain a product. Further, it can be produced by mixing and dissolving an organic acid and diclofenac sodium in crotamiton.

The invention's effect

The present invention provides a patch excellent in percutaneous absorption of diclofenac as an active ingredient by mixing diclofenac sodium and an organic acid which is solid at room temperature to a rubber-based pressure-sensitive adhesive. In addition, they have found that by adding crotamiton, a patch can be obtained which is excellent not only in percutaneous absorption of diclofenac but also in stability over time and is less irritating to the skin. Therefore, the patch of the present invention has excellent transdermal absorption of diclofenac, which is an active ingredient, as well as excellent stability over time, and has excellent anti-inflammatory and analgesic effects with little irritation to the skin. It is intended to provide a practical patch having excellent efficacy, safety and stability.

The patch of the present invention can be produced by a simple and stable method of kneading a crotamiton solution containing an active ingredient and an absorption promoter and a rubber-based pressure-sensitive adhesive. Brief Description of Drawings

FIG. 1 is a graph showing the results of a transdermal absorption test of the patch of the present invention and a comparative patch.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

Example 1 [0019] Experimental Example 1

Solubility test

The present inventors first examined the solubility of various solvents in diclofenac sodium and a solid organic acid at room temperature, taking tartaric acid as an example of a solid organic acid at room temperature.

The results are shown in Table 1 below.

[0020] [Table 1]

[0021] Among them, a solvent having a hydroxyl group is excluded from the selection because it is likely to form an ester with diclofenac sodium during storage, which is unfavorable as a solvent in the preparation of the present invention. As a result, N-methyl-2-pyrrolidone and crotamiton could be selected as preferred solvents.

Example 2

Production of Patch (1) of the Present Invention

The patch (1) of the present invention having the following composition was produced by the following method. First, 1 part of diclofenac sodium was dissolved by heating in 3 parts of crotamiton, while 0.4 part of citrate was dissolved by humidification in 1 part of crotamiton, and both solutions were combined into one solution. Further, cefsol (glycerin fatty acid ester, Nikko Chemicals) was added to this solution and mixed to obtain a uniform solution.

Styrene-isoprene-styrene block copolymer (SIS), polyisobutylene (PIB), liquid paraffin, and alicyclic petroleum resin are mixed and kneaded while heating. To this, the crotamiton solution prepared above was added and mixed uniformly to produce a composition to be an adhesive layer.

The pressure-sensitive adhesive composition obtained above was applied and spread on a support, covered with a liner, and cut into a suitable size to obtain a patch (1).

Composition

Diclofenac sodium 1 dissolved

Crotamitone 3 dissolution

Cuenoic acid 0.4 dissolved

Crotamitone 1 dissolution

Cefso 1 Nore 2

Styrene-isoprene-styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14

Liquid paraffin 32.3

Alicyclic petroleum resin 32. 3

Comparative Example 1 Comparative Patch (1)

A comparative patch (1) having the following compositional power was produced according to the method described in Example 2.

Diclofenac sodium 1 dissolved

Crotamiton 4 dissolution

Cefsol 2 dissolving

Styrene-isoprene-styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14 Liquid paraffin

Alicyclic petroleum resin

Example 3

Production of Patch (2) of the Present Invention

According to the method described in Example 2, a patch (2) of the present invention having the following composition was produced.

Composition

Diclofenac sodium 1 dissolved

Crotamitone 3 dissolution

Cuenoic acid 0.4 dissolved

Crotamitone 1 dissolution

Styrene Isoprene-styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14

Liquid paraffin 33.3

Alicyclic petroleum resin 33.3

Example 4

Production of Patch (3) of the Present Invention

According to the method described in Example 2, a patch (3) of the present invention having the following composition was produced.

Composition

Diclofenac sodium 1 dissolved

Crotamitone 3 dissolution

Tartaric acid 0.4 dissolved

Crotamitone 1 dissolution

Cefso 1 Nore 2

Styrene-isoprene-styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14

Liquid paraffin 32.3 Alicyclic petroleum resin 32. 3

Comparative Example 2

A comparative patch (2) having the following composition was produced according to the method described in Example 2.

Diclofenac sodium 1 dissolved

N-methyl-2-pyrrolidone 2 dissolution Cunic acid 0.4 dissolution

N-Methyl-2-pyrrolidone 1 Dissolution Cefsol mono 2

Styrene Isoprene Styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14

Liquid paraffin 32.3

Alicyclic petroleum resin 32. 3

Example 5

Production of Patch (4) of the Present Invention

According to the method described in Example 2, a patch (4) of the present invention having the following composition was produced.

Composition

Diclofenac sodium 1 dissolved

Crotamitone 3 dissolution

Tartaric acid 0.28 dissolved

Crotamitone 1 dissolution

Cefso 1 Nore 2

Styrene Isoprene Styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14

Liquid paraffin 32.36

Alicyclic petroleum resin 32. 36 Example 6

Production of Patch (5) of the Present Invention

According to the method described in Example 2, a patch (5) of the present invention having the following composition was produced.

Composition

Diclofenac sodium 1 dissolved

Crotamitone 3 dissolution

Cuenoic acid 0.4 dissolved

Crotamitone 1 dissolution

Cefso 1 Nore 2

Styrene Isoprene-styrene block copolymer (SIS) 14

Polyisobutylene (PIB) 14

Liquid paraffin 32.3

Hydrogenated corn rosin ester resin 32.3

Example 7

Experimental Example 2

In vitro skin permeation test

Test method

The skin on the side of the body of the hairless mouse was removed, fat on the dermis side was carefully removed, and the hair was attached to a flow-through cell in which water at 37 ° C was circulated around the outer periphery so that the dermis side became a receptor tank. The patch was applied to the stratum corneum side, and a phosphate buffer solution was passed through the receptor tank at 1 mL / hr, and the buffer solution was collected every 4 hours. From these samples, the drug concentration was quantified by the HPLC method, and the permeation rate (Flux) at each collection time was calculated by the following equation.

Flux = [Sample concentration (μg / mL) X Flow rate of 4hr (mL)] Z Application area of the preparation (cm ² ) X 4hr

Test condition:

Animals and skin: Shaved side skin of hairless mouse (female, 8 weeks old) (up to dermis) Number of cases: 4

Transmission cell: Vertical flow-through cell

Formulation ： 10mm diameter circle

Receptor solution: 50 mM phosphate buffer, pH 7.4

Test temperature: 37 ° C

The outline of the composition of the patch of the present invention and the comparative patch used in this test is shown in Table 2 below.

[Table 2]

FIG. 1 shows the results graphically. In FIG. 1, the horizontal axis indicates time (hour), and the vertical axis indicates transmission amount (

gZcm ² Z hours). The black square (country) indicates the patch (1) (Example 2) of the present invention, the black diamond (♦) indicates the patch (2) (Example 3) of the present invention, and the black circle (see) Indicates the patch (3) of the present invention (Example 4), and the black triangle mark ()) indicates the comparative patch (1) (Comparative Example 1). As a result, it can be seen that the patch of the present invention containing a solid organic acid at room temperature has extremely excellent transdermal absorbability.

Example 8

Experimental Example 3

Stability test

The storage stability of the patches obtained in Examples 4 and 5 was evaluated as follows. That is, the patch was stored at 25 ° C and 40 ° C, and a sample was collected one month later. From these samples, the drug concentration was quantified by the HPLC method, and the content before storage was calculated as the initial ratio (%), assuming that the content before storage was 100%, and the content after one month.

The results are shown in Table 3 below. Results of stability test of patch of the present invention

As a result, it was found that the patch of Example 3 having a large amount of tartaric acid had more excellent storage stability.

Example 9

[0034] Experimental example 4

Safety test

The patches of Example 2 and Comparative Example 2 were applied to the inside of the left and right upper arms of three healthy adult boys, respectively, and peeled 24 hours later. One hour after the exfoliation, the skin condition was observed and scored according to the following criteria. In addition, the ratio of the number of persons who recognized any skin reaction was defined as a positive rate (%).

++ Ten erythema edema, papules

+ Obvious erythema

Light erythema

No response

The results are shown in Table 4 below.

Table 4 Safety test results of the patch of the present invention

[¾4]

As a result, it was found that the patch of the present invention using crotamiton had extremely low skin irritation. Industrial applicability

INDUSTRIAL APPLICABILITY The present invention is used for a transdermal patch containing an anti-inflammatory analgesic, which is excellent in stability and transdermal absorbability and has little irritation to the skin, and is extremely useful in industry.

Claims

The scope of the claims

[1] In an anti-inflammatory analgesic patch that also becomes a rubber-based adhesive, the drug layer contains diclofenac sodium

An anti-inflammatory analgesic patch comprising an organic acid which is solid at room temperature and crotamiton.

[2] The anti-inflammatory analgesic patch according to [1], which is obtained by mixing and dissolving a solid organic acid and diclofenac sodium at room temperature in crotamiton and kneading the solution with a rubber-based adhesive. .

[3] The rubber-based adhesive is selected from polyisoprene, polyisobutylene, polybutadiene, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene block copolymer, and natural rubber. 3. The anti-inflammatory analgesic patch according to claim 1 or 2, which has more than one kind of power.

[4] The organic acid which is solid at room temperature is an organic hydroxy acid which is solid at room temperature.

V, the antiphlogistic analgesic patch according to the description above.

[5] The organic acid which is solid at room temperature is one or more selected from citric acid, tartaric acid, lactic acid, glycolic acid, succinic acid, maleic acid, and fumaric acid. An anti-inflammatory analgesic patch as described in Crab.

6. The anti-inflammatory analgesic patch according to claim 4, wherein the organic acid which is solid at room temperature is tartaric acid.